Elevated systolic pulmonary artery pressure (SPAP) after ST-segment elevation myocardial infarction (STEMI) has been associated with adverse outcome. However, little is known about the development of increased SPAP after STEMI treated with primary percutaneous coronary intervention. The aims of this study were to investigate the incidence and determinants of elevated SPAP (SPAP ‡36 The presence of elevated systolic pulmonary artery pressure (SPAP) after ST-segment elevation myocardial infarction (STEMI) has been associated with adverse outcome. 1e3 In addition, elevated SPAP may develop after STEMI due to increased left ventricular (LV) filling pressures due to LV systolic and diastolic dysfunction. 2e8 The adoption of primary percutaneous coronary intervention (PCI) as standard treatment of STEMI has led to limited infarct size, more preserved LV systolic and diastolic function and less frequently adverse LV remodeling at follow-up, 9 which may result in lower incidence of increased SPAP. However, this hypothesis remains unexplored. Furthermore, little is known about the development and the prognostic implications of incident elevated SPAP during follow-up after STEMI. Accordingly, the aims of the present evaluation were threefold (1) to assess the prevalence of elevated SPAP at baseline and at 12-month followup in patients with STEMI treated with primary PCI; (2) to assess contributing factors to the development of incident elevated SPAP during follow-up; and (3) to evaluate the prognostic implications of incident elevated SPAP during follow-up after STEMI.
The presence of elevated systolic pulmonary artery pressure (SPAP) after ST-segment elevation myocardial infarction (STEMI) has been associated with adverse outcome. 1e3 In addition, elevated SPAP may develop after STEMI due to increased left ventricular (LV) filling pressures due to LV systolic and diastolic dysfunction. 2e8 The adoption of primary percutaneous coronary intervention (PCI) as standard treatment of STEMI has led to limited infarct size, more preserved LV systolic and diastolic function and less frequently adverse LV remodeling at follow-up, 9 which may result in lower incidence of increased SPAP. However, this hypothesis remains unexplored. Furthermore, little is known about the development and the prognostic implications of incident elevated SPAP during follow-up after STEMI. Accordingly, the aims of the present evaluation were threefold (1) to assess the prevalence of elevated SPAP at baseline and at 12-month followup in patients with STEMI treated with primary PCI; (2) to assess contributing factors to the development of incident elevated SPAP during follow-up; and (3) to evaluate the prognostic implications of incident elevated SPAP during follow-up after STEMI.
Methods
The present evaluation included 705 patients with a first STEMI treated with primary PCI and with available echocardiograms at baseline and 12-month follow-up, in which measurement of SPAP was feasible. Patients with previous MI were excluded. Other exclusion criteria were out-ofhospital cardiac arrest, severe chronic obstructive pulmonary disease, lobectomy, preexisting pulmonary arterial hypertension, congenital heart disease, and preexisting severe valvular heart disease. Finally, patients with reinfarction before the 12-month echocardiogram were excluded. For this retrospective analysis of clinically acquired data, the institutional review board waived the need of patient written informed consent.
Images were obtained with the patient at rest in the left lateral decubitus position using a commercially available system (Vivid 7 and E9; General Electric-Vingmed, Horten, Norway). Data were acquired with 3.5 MHz or M5S transducers in the standard parasternal and apical views. Standard M-mode, 2-dimensional, color, pulsed, and continuous wave Doppler images were obtained and stored in cineloop format. Data analysis was performed offline with commercially available postprocessing data software (EchoPAC version 111.0.0; General Electric-Vingmed). SPAP was calculated by adding right ventricular (RV) pressure to right atrial pressure. RV pressure was estimated by calculating the systolic pressure gradient between the RV and right atrium by the maximum velocity of the regurgitant jet using the modified Bernoulli equation. 10 Right atrial pressure was estimated by measuring the diameter and the inspiratory collapse of the vena cava inferior. 10 Furthermore, RV dimensions and function were evaluated by measuring RV end-diastolic area, RV end-systolic area, right atrial area, and tricuspid annular plane systolic excursion in the apical 4-chamber view. 10 In addition, LV volumes and function were assessed by measuring the LV Data are presented as mean value AE SD and as frequencies and percentages. * p Values are provided for the comparisons of patients with and without incident elevated systolic pulmonary arterial pressure (SPAP) at 12-month followup (defined as SPAP !36 mm Hg).
† For this comparison, patients with elevated SPAP at both baseline and 12-month follow-up were excluded (n ¼ 19).
Coronary Artery Disease/Elevated SPAP in STEMIend-systolic and end-diastolic volumes, indexed to the body surface area, and LV ejection fraction (LVEF) using the biplane Simpson's method. 11 The wall motion score index was calculated as recommended by current guidelines. LV diastolic function was evaluated by obtaining peak early (E) and late (A) diastolic velocities and E-wave deceleration time. E 0 was assessed with tissue Doppler imaging at the septal side of the mitral annulus in the apical 4-chamber view, and E/E 0 ratio was calculated. 12 Moreover, according to the biplane Simpson's technique maximal left atrial volume was measured in the apical 4-chamber and 2-chamber views and indexed to the body surface area.
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The presence of significant valvular heart disease was evaluated according to the current guidelines. 11, 13, 14 After discharge, patients were followed up according to the institutional MISSION! protocol. 15 The study end point was all-cause mortality with the initial time set at the 12-month echocardiogram. Survival status was obtained through municipal civil registries. Lost to follow-up was considered in patients without data on the last 6 months. Data of these patients were included up to the last date of follow-up.
Continuous data are reported as mean AE SD or SEM, where appropriate, and categorical data as frequencies and percentages. Elevated SPAP was defined as !36 mm Hg. 16 The prevalence of elevated SPAP was assessed at baseline and at 12-month follow-up. Incident elevated SPAP at 12-month follow-up was defined as normal SPAP at baseline and elevated SPAP at the 12-month echocardiogram. Thereafter, patients with elevated SPAP at both baseline and 12-month follow-up were excluded from further analyses. Subsequently, the patient population was divided according to the presence or absence of incident elevated SPAP at 12-month follow-up. Differences in baseline clinical and echocardiographic characteristics between patients with and without incident elevated SPAP were assessed using the Student t test and chi-square test. Univariate and multivariate logistic regression analyses were performed to identify independent baseline clinical and echocardiographic correlates of incident elevated SPAP. Thereafter, cumulative survival rates were assessed using the KaplaneMeier method. The initial time was set at the 12-month echocardiogram, and the end of follow-up was set at the date of death from any cause or censored at December 31, 2012. Using a log-rank test, differences in cumulative survival rates in patients with or without incident elevated SPAP were assessed. Finally, univariate and multivariate Cox proportional hazards analyses were performed to identify clinical and 12-month echocardiographic determinants of all-cause mortality, and the relative risks were expressed as hazard ratios with associated 95% confidence intervals. Clinical and echocardiographic relevant univariate variables with a p <0.10 were included in a multivariate Cox regression model. For multivariate models, all univariate variables with a p <0.10 were included in a multivariate logistic regression model. A correlation coefficient of <0.7 was set to avoid multicollinearity between univariate correlates. To avoid multicollinearity between univariate parameters, a correlation coefficient of <0.7 was set. In addition, LV end-diastolic volume, LV end-systolic volume, and LVEF were not included in the same model to avoid collinearity. Likewise, different parameters of diastolic function were not included in the same model. A p value <0.05 was considered statistically significant, and all tests were 2 sided. All statistical analyses were performed with SPSS software, version 20.0 (SPSS Inc., Chicago, Illinois).
Results
A total of 705 patients with a first STEMI treated with PCI were evaluated. Table 1 summarizes the baseline clinical and echocardiographic characteristics of the patient population. In the overall population, there were no significant changes in SPAP at baseline and 12-month follow-up (25 AE 9 mm Hg and 25 AE 8 mm Hg, respectively). The prevalence of elevated SPAP (defined as !36 mm Hg) at baseline and 12-month follow-up was 10% (n ¼ 71) and 8% (n ¼ 57), respectively ( Figure 1 ). Nineteen patients with elevated SPAP at baseline and 12-month follow-up were hereafter excluded from further analyses (Figure 1 ). The incidence of elevated SPAP at follow-up was 5% (n ¼ 38) and were hereafter referred to as patients with incident elevated SPAP.
Baseline characteristics of patients with and without incident elevated SPAP are presented in Table 1 . Patients with incident elevated SPAP were significantly older and had a higher prevalence of hypertension in comparison to patients with normal SPAP. Both groups were comparable for other cardiovascular risk factors, culprit vessel and mean peak cardiac enzymes although patients with incident elevated SPAP tended to show higher peak cardiac troponin T levels. At discharge, there was no difference in use of medication (Table 1) .
Regarding echocardiographic characteristics, patients with incident elevated SPAP showed a lower LVEF and larger left atrial volumes at baseline compared with their counterparts (Table 1) . Furthermore, in patients with incident elevated SPAP, there was a higher prevalence of moderate to severe mitral regurgitation grade compared with the group with normal SPAP. There were no significant differences in RV volumes and function at baseline between the 2 groups (Table 1) . Table 2 demonstrates the univariate and multivariate logistic regression analyses to identify correlates of incident Figure 1 . Prevalence of elevated systolic pulmonary arterial pressure (SPAP; defined as SPAP !36 mm Hg) at baseline and at 12-month followup after STEMI. The prevalence of newly developed elevated SPAP at 12 months (incident elevated SPAP) is 5% (n ¼ 38). The absolute change in mean SPAP from baseline to 12-month follow-up is also presented in the figure as mean AE standard error. st. error ¼ standard error.
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The American Journal of Cardiology (www.ajconline.org) elevated SPAP at 12-month follow-up. Age, hypertension, peak cardiac troponin T level, LVEF, and left atrial volume (all with p <0.10 at univariate analysis) were included in the final multivariate model. Independent determinants of incident elevated SPAP were age, hypertension, LVEF, and left atrial volume (Table 2) . During a median follow-up of 62 months (interquartile range 29 to 75), 43 patients (6%) died. The initial time of follow-up was set at the 12-month echocardiogram. There were no patients lost to follow-up. The cumulative survival rates in the patient group with normal SPAP were 99%, 98%, and 96% at 1, 3, and 5 years of follow-up, respectively. In comparison, the patient group with incident elevated SPAP had significantly worse outcome with survival rates at 1 year of 97%, at 3 years of 89%, and at 5 years follow-up of 76% (log-rank p <0.001, Figure 2 ). Univariate and multivariate Cox regression analyses were performed to determine the prognostic value of incident elevated SPAP adjusted for other clinical and echocardiographic parameters. Significant univariate determinants of all-cause mortality are summarized in Table 3 . Age, multivessel disease, LVEF, left atrial volume, and SPAP !36 mm Hg were introduced in a multivariate model (Table 3 ). In the multivariate model, age, LVEF, and SPAP !36 mm Hg were independently associated with all-cause mortality (Table 3 ). In addition, incident elevated SPAP at 12-month follow-up was associated with a fourfold adjusted increased risk of all-cause mortality compared to patients with normal SPAP (Table 3) .
Discussion
The present study demonstrated that the incidence of elevated SPAP after STEMI is low. Independent correlates of incident elevated SPAP were age, hypertension, baseline LVEF, and left atrial volume. Importantly, the development of elevated SPAP after STEMI was independently associated with increased risk of all-cause mortality.
The prevalence of elevated SPAP after acute MI ranges from 21% to 45%, depending on the definition used.
1e3,17
The heterogeneous populations included in previous studies (STEMI and non-STEMI patients who were treated with either thrombolysis or PCI) may explain the disparate prevalences. In contrast, the present study, evaluating only STEMI patients treated with primary PCI, showed a 10% prevalence of elevated SPAP after STEMI. Primary PCI has demonstrated to limit infarct size and preserve LV function. 18, 19 Since both LV systolic and diastolic dysfunction may lead to increased LV filling pressures and elevated SPAP, 2e8 the systematic use of primary PCI may result in a decreased prevalence of elevated SPAP. Mutlak et al 3 reported that in 1,054 patients (82% STEMI) admitted with acute coronary syndrome, the prevalence of SPAP >35 mm Hg measured by echocardiography was 45%. Patients with low SPAP were significantly more often treated with percutaneous coronary revascularization compared to patients with elevated SPAP. Similar results were also observed in a series of 536 acute MI patients where the prevalences of moderately elevated (31 to 55 mm Hg) and severely elevated RV systolic pressure (>55 mm Hg) were 54% and 21%, respectively. 2 Patients with low RV systolic pressures were more often treated with primary PCI, whereas patients who received thrombolytic therapy had similar values of RV pressures than those who did not receive any revascularization therapy. The inclusion of only STEMI patients treated with primary PCI in the present study may have led to a lower prevalence of elevated SPAP directly after STEMI. Furthermore, the exclusion of patients who did not survive the first year after the index STEMI may be an important bias since less sicker patients may have Coronary Artery Disease/Elevated SPAP in STEMIbeen selected, as reflected by a relatively preserved LVEF.
Together with the exclusion of other co-morbidities that may be associated with increased SPAP (i.e., chronic pulmonary obstructive disease), this may explain the relatively low prevalence of increased SPAP.
Little is known about the development of elevated SPAP during follow-up after STEMI, especially in patients treated with primary PCI. In the present evaluation, 8% of the patient population had elevated SPAP at 12-month follow-up. Of these, 38 patients (5% of the total population) had newly developed elevated SPAP (or incident elevated SPAP). Independent associates of incident elevated SPAP at 12-month follow-up were age, hypertension, lower LVEF, and higher left atrial volume as a parameter of diastolic function. The association between age and reduced LVEF with the presence of elevated SPAP directly measured after acute MI has been previously described. 3 Furthermore, previous studies showed a correlation between the presence of LV diastolic dysfunction and post-MIeelevated SPAP. 2, 3, 17 However, it should be noted that these studies evaluated the prevalence of elevated SPAP directly measured after acute MI, whereas the present study assessed the prevalence of elevated SPAP at 12-month follow-up. Andersen et al 20 showed that in patients with recent MI and preserved LVEF, those with LV diastolic dysfunction (reflected by increased E/E 0 ratio and left atrial volume) had higher values of invasively measured SPAP compared to patients without diastolic dysfunction. Interestingly, patients with recent MI and LV diastolic dysfunction had a higher prevalence of hypertension compared to patients without diastolic dysfunction, which may contribute to increased LV afterload and left atrial pressure. 20 In line, the present study showed that hypertension was an independently associated with incident elevated SPAP. Furthermore, patients with elevated SPAP had more frequently significant mitral regurgitation than their counterparts although the difference was not statistically significant. Nevertheless, this may have contributed to the elevated SPAP.
The presence of elevated SPAP has been associated with increased risk of mortality and morbidity in patients after STEMI. Mutlak et al 3 reported an increased risk for readmission for heart failure at 1 year follow-up in patients with SPAP >35 mm Hg measured after acute MI. Similarly, Carasso et al 1 demonstrated that patients who died within 30 days after acute MI or acute coronary syndrome had significantly higher SPAP compared with patients without event. Moller et al 2 confirmed these results by showing that an increase in RV systolic pressure was an independent predictor of mortality after adjusting for conventional risk factors including LV diastolic and systolic function. The present study provides novel evidence by reporting on the development of new elevated SPAP after STEMI and its association with a fourfold increased risk for all-cause mortality after adjusting for important clinical and echocardiographic parameters. These results suggest that during 1-year follow-up, routine echocardiographic surveillance of patients with first STEMI treated by PCI may help to identify those subjects who are at risk for developing increased SPAP. Furthermore, additional testing including exercise echocardiography to evaluate pulmonary hypertension may a valuable tool in patients with relatively preserved LVEF and disproportionate heart failure symptoms. A previous study has shown that exercise-induced pulmonary hypertension was associated with 5.3-fold increased risk for cardiovascular mortality in patients with secondary mitral regurgitation. 21 In the present study, patients with increased SPAP had more frequently significant mitral regurgitation. Exercise echocardiography would have helped to identify a larger number of patients with increased SPAP particularly in the subgroup of patients with more than mild secondary mitral regurgitation.
Some limitations should be acknowledged. The present single-center study was retrospective. However, the present evaluation consisted of a large contemporary cohort of patients with STEMI treated according to the current guidelines. Although patients with known clinical conditions that might affect SPAP independently of the MI were excluded by careful clinical review, further evaluation by means of functional lung tests, for example, were not performed and some patients may have been underdiagnosed. Furthermore, changes in hemodynamics during the acute phase and follow-up may have had an influence on the prevalence and incidence of elevated SPAP. Data on the use of loop diuretics and/or aldosterone antagonists were not systematically collected. However, the analyses were corrected for other load-dependent parameters.
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